IMPROVEd Timing On Vytorin Outcomes Data?
This article was originally published in The Pink Sheet Daily
Executive Summary
Full results from the massive study will be delayed a year, but an earlier interim analysis could help resolve questions about the safety and efficacy of Merck's cholesterol drug.
You may also be interested in...
FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Vytorin Re-Endorsed By FDA Despite Lack Of Impact On Carotid Artery Thickness
Agency offers three possible explanations for why a reduction in LDL failed to translate into a drop in cIMT.